Vireo Growth Inc · CSE:VREO

Vireo Growth — Q1 2025 Earnings Presentation

8 slides from Vireo Growth's earnings presentation, May 9, 2025

  1. Slide 1: Q1 2025 Results Conference Call

    Q1 2025 Results Conference Call May 9, 2025 CSE: VREO OTCQX: VREOF

  2. Slide 2: Forward Looking Statement Disclaimer

    Forward Looking Statement Disclaimer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs, and opinions which are forward- looking, and which reflect current estimates, expectations, and projections about future events, referred to herein

  3. Slide 3: First Quarter and Recent Business Highlights

    First Quarter and Recent Business Highlights • Q1 results were in line with expectations for Vireo’s established core markets • Q1 performance was driven by continued growth in Maryland, stable performance in Minnesota, medical sales declines in New York, and the commencement of adult use sales in N

  4. Slide 4: Summary Financials

    Summary Financials Summary of Key Financial Metrics Three Months Ended US $ in millions March 31, 2025 2024 Variance GAAP Revenue $24.5 $24.1 1.9% GAAP Gross Profit $12.4 $12.2 1.4% Gross Profit Margin 50.6% 50.8% -20 bps SG&A Expenses $7.5 $7.1 6.0% SG&A Expenses (% of Sales) 30.5% 29.3% 120 bps Op

  5. Slide 5: State-by-State Revenue Performance

    State-by-State Revenue Performance1 Q1 YoY Q1 Sequential 1Q25 1Q24 %∆ 1Q25 4Q24 %∆ Total Retail: $19,233,641 $19,599,440 (2) $19,233,641 $19,375,309 (1) Minnesota $11,209,204 $10,977,089 2 $11,209,204 $11,221,254 0 Maryland $6,819,392 $6,801,082 0 $6,819,392 $6,846,072 0 New York $1,205,045 $1,821,2

  6. Slide 6: Capitalization Table as of March 31, 2025

    Capitalization Table as of March 31, 2025 Vireo Growth Inc. Capitalization Table* FD Treasury Method Shares Outstanding (@ stock price of US $0.50) 472,078,412 Stock Price US $0.45 Market Cap ($ USD) $212.4M Balance Sheet as of 3/31/25: Cash Balance $86.3M Net Long-Term Debt & Convertible Debt $72.5

  7. Slide 7: EBITDA and Adjusted EBITDA Reconciliation

    EBITDA and Adjusted EBITDA Reconciliation Three Months Ended March 31, 2025 2024 Net income (loss) $ (6,508,790) $ (6,711,460) Interest expense, net 7,599,517 8,722,637 Income taxes 1,675,000 3,945,000 Depreciation & Amortization 257,134 253,581 Depreciation and amortization included in cost of good

  8. Slide 8: CSE: VREO OTCQX: VREOF

    Wr VIFeCO CSE: VREO OTCQX: VREOF

Vireo Growth — Q1 2025 Earnings Presentation on 6ix